Abcellera Biologics Ownership
| ABCL Stock | USD 4.48 0.58 14.87% |
Shares in Circulation | First Issued 2019-03-31 | Previous Quarter 295.8 M | Current Value 297.7 M | Avarage Shares Outstanding 269.9 M | Quarterly Volatility 50.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Abcellera | Build AI portfolio with Abcellera Stock |
Abcellera Stock Ownership Analysis
About 23.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.31. Some equities with similar Price to Book (P/B) outperform the market in the long run. Abcellera Biologics has Price/Earnings To Growth (PEG) ratio of 2.22. The entity recorded a loss per share of 0.56. The firm had not issued any dividends in recent years. AbCellera Biologics Inc. develops antibody discovery platform. The company was incorporated in 2012 and is headquartered in Vancouver, Canada. Abcellera Biologics is traded on NASDAQ Exchange in the United States. For more info on Abcellera Biologics please contact Carl Hansen at 604 559 9005 or go to https://www.abcellera.com.Besides selling stocks to institutional investors, Abcellera Biologics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Abcellera Biologics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Abcellera Biologics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Abcellera Biologics Quarterly Liabilities And Stockholders Equity |
|
Abcellera Biologics Insider Trades History
About 23.0% of Abcellera Biologics are currently held by insiders. Unlike Abcellera Biologics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Abcellera Biologics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Abcellera Biologics' insider trades
Abcellera Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Abcellera Biologics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Abcellera Biologics backward and forwards among themselves. Abcellera Biologics' institutional investor refers to the entity that pools money to purchase Abcellera Biologics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Prosight Management, Lp | 2025-03-31 | 2.8 M | Two Sigma Advisers, Llc | 2025-03-31 | 2.6 M | Tang Capital Management Llc | 2025-03-31 | 2.6 M | Citadel Advisors Llc | 2025-03-31 | 1.8 M | Guardian Partners Inc. | 2025-03-31 | 1.8 M | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 1.3 M | Norges Bank | 2024-12-31 | 1.3 M | Novo A/s | 2025-03-31 | 1.1 M | Federated Hermes Inc | 2025-03-31 | 947.8 K | Baker Bros Advisors Lp | 2025-03-31 | 27.5 M | Ing Investment Management Llc | 2025-03-31 | 21.2 M |
Abcellera Biologics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Abcellera Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Abcellera Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Abcellera Biologics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Abcellera Biologics Outstanding Bonds
Abcellera Biologics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Abcellera Biologics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Abcellera bonds can be classified according to their maturity, which is the date when Abcellera Biologics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcellera Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.459 | Earnings Share (0.56) | Revenue Per Share | Quarterly Revenue Growth (0.57) | Return On Assets |
The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.